Factors Affecting the Price of Xagrid
It is extensively metabolized in the liver. Patients with hepatic impairment may have increased systemic exposure to anagrelide. For patients with mild to moderate hepatic impairment, the risks of treatment and potential benefits should be weighed, the dosage should be reduced, and adverse cardiovascular effects or other toxic manifestations should be closely monitored. Anagrelide is contraindicated in patients with severe hepatic impairment.
